TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06127303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab treatment (240mg intravenously every 3 weeks) started on day 3 after cryoablation, until occurrence of termination event specified in the protocol.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: The ablation was performed on the first day of each cycle, and the target lesions were comprehensively screened for cryoablation based on the location and size of the lesions.
Study: NCT06063876

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Induction of experimental peri-implant mucositis
Description: Patients will refrain from oral hygiene measures at the implant sites for 3 weeks to induce peri-implant mucositis, by using a stent in the included implant during oral hygiene.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resolution of experimental peri-implant mucositis
Description: Patients will reinstitute oral hygiene measures, receive an oral prophylaxis and oral hygiene instructions and will be evaluated during 3 weeks.
Study: NCT06077214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment with liposomal bupivacaine
Description: Patients will randomly be treated with either liposomal bupivacaine (study drug) after undergoing bariatric surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment with standard bupivacaine
Description: Patients will randomly be treated with standard bupivacaine after undergoing bariatric surgery.
Study: NCT06106568

Intervention type: PROCEDURE
Intervention: EOB-MRI
Description: Retrospective analysis for pancreatic cancer patients who had a record of EOB-MRI in the Medical Data Vision (MDV) database in Japan

Intervention type: PROCEDURE
Intervention: EOB-MRI
Description: Retrospective analysis for pancreatic cancer patients who had a record of EOB-MRI in the Medical Data Vision (MDV) database in Japan

Intervention type: PROCEDURE
Intervention: EOB-MRI
Description: Retrospective analysis for pancreatic cancer patients who had a record of EOB-MRI in the Medical Data Vision (MDV) database in Japan

Intervention type: PROCEDURE
Intervention: EOB-MRI
Description: Retrospective analysis for pancreatic cancer patients who had a record of EOB-MRI in the Medical Data Vision (MDV) database in Japan

Intervention type: PROCEDURE
Intervention: Surgery
Description: Retrospective analysis for pancreatic cancer patients who had a record of any surgery for the pancreatic cancer in the Medical Data Vision (MDV) database in Japan

Intervention type: PROCEDURE
Intervention: Surgery
Description: Retrospective analysis for pancreatic cancer patients who had a record of any surgery for the pancreatic cancer in the Medical Data Vision (MDV) database in Japan

Intervention type: PROCEDURE
Intervention: Open-close Laparotomy
Description: Retrospective analysis for pancreatic cancer patients who had a record of an open-close laparotomy in the Medical Data Vision (MDV) database in Japan

Intervention type: PROCEDURE
Intervention: Open-close Laparotomy
Description: Retrospective analysis for pancreatic cancer patients who had a record of an open-close laparotomy in the Medical Data Vision (MDV) database in Japan
Study: NCT06549647

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low caloric diet
Description: A low caloric diet of 1200 Kcal will be followed by participant for 3 months. The dietary intervention follows a macronutrient ratio of 15% protein, 30% fat, and 55% carbohydrates. Participants are advised to consume 170-240g of complex carbohydrates, 60-100g of fat, and 55-93g of protein per day, with 20-35g of fiber. Patients are also advised to limit salt, tea, and caffeine intake, and receive supplemental vitamins to prevent deficiencies.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: low caloric diet
Description: A low caloric diet of 1200 Kcal will be followed by participant for 3 months. The dietary intervention follows a macronutrient ratio of 15% protein, 30% fat, and 55% carbohydrates. Participants are advised to consume 170-240g of complex carbohydrates, 60-100g of fat, and 55-93g of protein per day, with 20-35g of fiber. Patients are also advised to limit salt, tea, and caffeine intake, and receive supplemental vitamins to prevent deficiencies.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo laser acupoint stimulation
Description: Placebo laser acupoint stimulation will be used for all participants in group (A).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laser Acupuncture
Description: Eazyone EZ1 level laser will be used for the treatment procedures for all participants in group (B) only. Every participant in group (B) will be instructed briefly about the effect of laser acupoints therapy to gain her confidence and co-operation. It will be applied with infrared laser with 830 nm wavelength, 5 W power output and 0.5 J energy on the following acupoints while the patient lie in supine lying position. The head of the machine will be applied perpendicularly on each point for 1 min (17 min total), 3 times/ week for 4 weeks.
Study: NCT05139732

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging (MRI)
Description: In order to investigate the metabolic profile, magnetic resonance spectroscopy (MRS) will be applied. Functional MRI (fMRI) allows to indirectly track cell activation measuring the blood-level dependent signal changes followed spontaneously (in resting state) or evoked by a task. Diffusion weighted imaging (DWI) is based on the differences in motion of the water molecules given by the underlying microarchitecture of the nervous tissue. Diffusion tensor imaging (DTI) allows visualisation of the nerve bundles and alterations thereof. Thus, microstructural alterations can be measured.
Study: NCT05618301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Motixafortide
Description: Motixafortide is to be administered as a subcutaneous injection at a dose of 1.25 mg/kg
Study: NCT05382286

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Administered intravenously
Study: NCT06298396

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Program using default MAP
Description: Each MAP uses a specific combination of stimulation parameters and electrode mode.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Program using low-power 1 (LP1) MAP
Description: Each MAP uses a specific combination of stimulation parameters and electrode mode.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Program using low-power 2 (LP2) MAP
Description: Each MAP uses a specific combination of stimulation parameters and electrode mode.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Program using low-power 3 (LP3) MAP
Description: Each MAP uses a specific combination of stimulation parameters and electrode mode.
Study: NCT06512363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: Ramelteon 8 mg, tablets, orally, once nightly for up to 5 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ramelteon placebo
Description: Ramelteon placebo-matching tablets, orally, once nightly for up to 5 weeks.
Study: NCT06316570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Early Dual Antiplatelet Therapy
Description: Day 1(within 6.0 hours of onset, before or after intravenous thrombolysis) : Ticagrelor (180mg) + Aspirin (100mg), one dose;~Days 2-7: Ticagrelor (90mg/time, twice/day) + open-label Aspirin (100mg/time, once/day) ;~Days 8-90: open-label Aspirin (100mg/time, once/day).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Day 1(within 6.0 hours of onset, before or after intravenous thrombolysis) : Placebo of Ticagrelor (180mg) + Placebo of Aspirin (100mg), one dose;~Days 2-7: Placebo of Ticagrelor (90mg/time, twice/day) + open-label Aspirin (100mg/time, once/day) ;~Days 8-90: open-label Aspirin (100mg/time, once/day).
Study: NCT05064618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Am80
Description: medicine taken internally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Am80
Description: medicine taken internally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered intravenously at a dose of 1000mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered intravenously at a dose of 1000mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Description: Administered intravenously at a dose of 125mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Description: Administered intravenously at a dose of 125mg/m2
Study: NCT05003700

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hepatic arterial infusion chemotherapy
Description: administration of oxaliplatin and raltitrexed via the tumor feeding arteries every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 8 mg once daily (QD) oral dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: 200mg intravenously every 3 weeks.
Study: NCT06637059

Intervention type: OTHER
Intervention: observational study
Description: observation alone

Intervention type: OTHER
Intervention: observational study
Description: observation alone

Intervention type: OTHER
Intervention: observational study
Description: observation alone
Study: NCT06638918

Intervention type: DEVICE
Intervention: Virtual Reality
Description: The virtual reality (VR) intervention administers graded motor imagery (GMI) treatment for phantom limb pain. It consists of three stages: left right sorting task (a sorting task where participants sort images of left and right feet), explicit motor imagery (a series of guided imagery exercises administered via audio to facilitate focus on the phantom limb), and the limb simulation task (where participants perform a series of exercises with virtual legs to create the illusion of movement in their phantom limb). The limb simulation stage can also be conducted with leg trackers to generate a higher degree of illusion in the virtual legs.
Study: NCT06645080

Intervention type: OTHER
Intervention: Focus group or interview participation
Description: 90 minute focus group or 60 minute interview participation
Study: NCT04030052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nuwiq (low dose protocol)
Description: After receiving HEMLIBRA® for 1-6 months, rFVIII (NUWIQ®) will be given at low dose (25 ±5 units/kg/dose) every 7-14 days as part of a low dose factor exposure program and for on demand use for acute bleeding episodes/procedures. NUWIQ® will be administered intravenously (IV) via peripheral infusion. If the infant has a central line such as a PICC line or mediport this can be used.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEMLIBRA
Description: Four weekly subcutaneous (SQ) injections of HEMLIBRA® loading doses of 3 mg/kg will be given. A total of 12 mg/kg within the first month is allowed for the loading doses. Maintenance dosing will follow, and will either be 1.5 mg/kg/dose weekly, 3 mg/kg/dose biweekly (every 2 weeks), or 6 mg/kg/dose every 4 weeks depending on the recommended dosing.
Study: NCT06645080

Intervention type: OTHER
Intervention: Focus group or interview participation
Description: 90 minute focus group or 60 minute interview participation

Intervention type: OTHER
Intervention: Delphi survey participation
Description: Participation in a modified two-round Delphi technique. Optional third round in the event of insufficient agreement in the second round.
Study: NCT06275958

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doublet Chemotherapy, Standard Dose (100%)
Description: Capecitabine 1000mg / m2 oral at day 1-14 (every 3 weeks) Oxaliplatin 130mg/m2 at day 1 (every 3 weeks) OR 5-FU 400mg/m2 IV bolus at day 1 followed by 2400mg/m2 in 46 hours (every 2 weeks) Leucovorin 400mg/m2 day 1 (every 2 weeks) Oxaliplatin 85mg/m2 day 1 (every 2 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doublet Chemotherapy, Dose-reduced (75%)
Description: 75% of: Capecitabine 1000mg / m2 oral at day 1-14 (every 3 weeks) Oxaliplatin 130mg/m2 at day 1 (every 3 weeks) OR 5-FU 400mg/m2 IV bolus at day 1 followed by 2400mg/m2 in 46 hours (every 2 weeks) Leucovorin 400mg/m2 day 1 (every 2 weeks) Oxaliplatin 85mg/m2 day 1 (every 2 weeks)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Monotherapy, Standard Dose (100%)
Description: - Capecitabine 1000mg/m2 oral at day 1-14 (every 3 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monotherapy, Dose-reduced (75%)
Description: 75% of:~- Capecitabine 1000mg/m2 oral at day 1-14 (every 3 weeks)
Study: NCT06187714

Intervention type: PROCEDURE
Intervention: caudal block rate
Description: optic nerve sheath diameter measurement according to caudal block rate

Intervention type: PROCEDURE
Intervention: caudal block rate
Description: optic nerve sheath diameter measurement according to caudal block rate
Study: NCT05822245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PER-001 Intravitreal Implant - Low Dose
Description: PER-001 Low Dose Intravitreal Implant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PER-001 Intravitreal Implant - Low Dose
Description: PER-001 Low Dose Intravitreal Implant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PER-001 Intravitreal Implant - High Dose
Description: PER-001 High Dose Intravitreal Implant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PER-001 Intravitreal Implant - High Dose
Description: PER-001 High Dose Intravitreal Implant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PER-001 Intravitreal Implant - Sham
Description: PER-001 Intravitreal Sham

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PER-001 Intravitreal Implant - Sham
Description: PER-001 Intravitreal Sham
Study: NCT04030052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEMLIBRA
Description: Four weekly subcutaneous (SQ) injections of HEMLIBRA® loading doses of 3 mg/kg will be given. A total of 12 mg/kg within the first month is allowed for the loading doses. Maintenance dosing will follow, and will either be 1.5 mg/kg/dose weekly, 3 mg/kg/dose biweekly (every 2 weeks), or 6 mg/kg/dose every 4 weeks depending on the recommended dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nuwiq (Atlanta protocol)
Description: After completing HEMLIBRA® loading doses, participants will receive intravenous (IV) infusions of NUWIQ® 3 times per week, 100 units/kg the Atlanta protocol. Infusions will be given at least 36 hours from the previous NUWIQ® injection. Participants will continue on the HEMLIBRA® SQ - NUWIQ® IV treatment regimen for up to 12 months of NUWIQ® treatment.
Study: NCT05023018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NEO100
Description: NEO100 is a purified form of perillyl alcohol.
Study: NCT05013138

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training for ACEs and study procedures
Description: The providers will lead a resilience-based conversation discussion regarding the impact of caregiver ACEs, after receiving training for ACEs and study procedures.~The first training component will provide an overview of ACEs using the ACE Interface Training. The second training component will address the implementation of the caregiver ACEs screening in the clinic.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Training on study procedures
Description: Instead of ACEs training, standard of care providers will undergo training on study procedures including obtaining survey instruments from caregivers and proper storage of survey instruments. This training will stress the importance of not reviewing caregiver ACE scores and minimizing possible treatment contamination.
Study: NCT00627549

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Avaulta (surgical procedure using a mesh implant)
Description: The use of Avaulta

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional surgery (anterior repair)
Description: Anterior repair surgery
Study: NCT05891860

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Participation in virtual rounds
Description: Virtual participation in daily ICU team rounds
Study: NCT05475925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR-01
Description: DR-01 is a non-fucosylated, human immunoglobulin G1 (IgG1) monoclonal antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR-01
Description: DR-01 is a non-fucosylated, human immunoglobulin G1 (IgG1) monoclonal antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR-01
Description: DR-01 is a non-fucosylated, human immunoglobulin G1 (IgG1) monoclonal antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR-01
Description: DR-01 is a non-fucosylated, human immunoglobulin G1 (IgG1) monoclonal antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR-01
Description: DR-01 is a non-fucosylated, human immunoglobulin G1 (IgG1) monoclonal antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR-01
Description: DR-01 is a non-fucosylated, human immunoglobulin G1 (IgG1) monoclonal antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR-01
Description: DR-01 is a non-fucosylated, human immunoglobulin G1 (IgG1) monoclonal antibody.
Study: NCT06159608

Intervention type: DRUG
Group type: OTHER
Intervention: Local heating + L-NAME (NG-nitro-L-arginine methyl ester; nitric oxide synthase inhibitor)
Description: Differences in endothelium- and nitric oxide (NO)-dependent dilation between groups

Intervention type: DRUG
Group type: OTHER
Intervention: Local heating + L-NAME (NG-nitro-L-arginine methyl ester; nitric oxide synthase inhibitor)
Description: Differences in endothelium- and nitric oxide (NO)-dependent dilation between groups

Intervention type: DRUG
Group type: OTHER
Intervention: Local heating + L-NAME (NG-nitro-L-arginine methyl ester; nitric oxide synthase inhibitor)
Description: Differences in endothelium- and nitric oxide (NO)-dependent dilation between groups

Intervention type: DRUG
Group type: OTHER
Intervention: Local heating + L-NAME (NG-nitro-L-arginine methyl ester; nitric oxide synthase inhibitor)
Description: Differences in endothelium- and nitric oxide (NO)-dependent dilation between groups

Intervention type: OTHER
Group type: OTHER
Intervention: Chronic estrogen exposure
Description: differences in urine estrogen levels across the menstrual cycle between women groups only

Intervention type: OTHER
Group type: OTHER
Intervention: Chronic estrogen exposure
Description: differences in urine estrogen levels across the menstrual cycle between women groups only
Study: NCT05590195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preforpro
Description: Preforpro will be investigated to improve vaginal health in women with BV.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules manufactured to look like Preforpro capsules
Study: NCT06570720

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol-focused Support of Survivors in Sororities Training (ASSIST)
Description: A web-based intervention that includes sorority and individual values, personalized normative feedback (adapted to address sexual assault, support, and acceptability of encouraging peer drinking), psychoeducation on sexual assault and alcohol, and skills training in behaviors to support sexual assault survivors without heavy drinking.
Study: NCT06312254

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical lidocaine 5%
Description: Drug is used to pharmacologically modulate peripheral sensory afferents

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical Phenytoin 10%
Description: Drug is used to pharmacologically modulate peripheral sensory afferents

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical Mepyramine 2%
Description: Drug is used to pharmacologically modulate peripheral sensory afferents
Study: NCT06334029

Intervention type: DIAGNOSTIC_TEST
Intervention: Functional and structural Connectome
Description: Reconstruction of EEG derived functional relationship between brain regions (functional connectome). Reconstruction of thickness covariance across brain regions (structural connectome)

Intervention type: DIAGNOSTIC_TEST
Intervention: Functional and structural Connectome
Description: Reconstruction of EEG derived functional relationship between brain regions (functional connectome). Reconstruction of thickness covariance across brain regions (structural connectome)
Study: NCT06312254

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Topical Placebo
Description: Drug is used as control
Study: NCT06167746

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Digital Health Information (DHI)
Description: Digital health information websites.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital Health Information (DHI)
Description: Digital health information websites.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Health Coach for You
Description: Study participants in the intervention group will receive 10-session virtual health coaching intervention session delivered over 6 months with the goal of improving caregiver self-care and coping, decreasing stress, and improving the hospital-to-home experience The 10 sessions are on average 60 minutes and cover the following topics: care transitions, caregiving demand, self-care, and coping.
Study: NCT04932759

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: music listening
Description: music listening during dental treatment
Study: NCT06203574

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-NOTA-T4 or [18F]AlF-RESCA-T4
Description: The dose of \[68Ga\]Ga-NOTA-T4 or \[18F\]AlF-RESCA-T4 was calculated based on the patient's body weight to be 3.7 MBq \[0.1 mCi\]/kg, and the method of administration was intravenous push, with one single imaging administration.
Study: NCT05618301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natalizumab
Description: Natalizumab will be administered as an IV infusion at a flat dose of 300 mg

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Leukapheresis consisting of a 1 Blood Volume procedure